Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 2NET 1Genitourinary 1Dermatologic 1

Conditions

Pituitary Neoplasms 6Acromegaly 5Neuroendocrine Tumors 3Carcinoid Tumor 3Prostatic Neoplasms 2Pituitary ACTH Hypersecretion 2Growth Disorders 2Gigantism 2Gastro-enteropancreatic neuroendocrine tumor 2Serotonin Syndrome 1Pancreatic Neoplasms 1Neuroectodermal Tumors, Primitive 1Neoplasms 1Nelson Syndrome 1Melanoma 1Lymphoma, Follicular 1Dumping Syndrome 1Carcinoma, Neuroendocrine 1Adrenocortical Hyperfunction 1ACTH Syndrome, Ectopic 1

Interventions

relacorilant 3Mifepristone 3Corlux 3pasireotide 2Cabergoline 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Pituitary ACTH Hypersecretion × pasireotide × Clear all
NCT01794793 2024-10-01

Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies

RECORDATI GROUP

Phase 4 Completed
337 enrolled 8 charts
DermatologicEndocrineGenitourinaryNET

Acromegaly, Dumping Syndrome, Melanoma, Neoplasms, Pituitary Neoplasms, Prostatic Neoplasms, Neuroendocrine Tumors, Pituitary ACTH Hypersecretion

NCT01915303 2020-09-18

Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease

Novartis

Phase 2 Terminated
68 enrolled 25 charts
Endocrine

Adrenocortical Hyperfunction, Pituitary Neoplasms, Pituitary ACTH Hypersecretion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡